drugset / Trial / NCT02464670
Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers
Phase 1
Completed
240 enrolled
Inovio Pharmaceuticals
Defense Advanced Research Projects Agency · collabGeneOne Life Science, Inc. · collab
RandomizedSequentialDouble-blindPrevention
Summary
This study evaluates whether INO-4212 and its components INO-4201 and INO-4202 administered intramuscularly (IM) or intradermally (ID) followed by electroporation (EP) will be well tolerated and immunogenic.
Timeline
- Start
- 2015-05
- Primary completion
- 2018-05-24
- Completion
- 2018-05-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INO-4201 | Vaccine | 0.8 mg | Intramuscular |
| Subject | INO-4201 | Vaccine | 1 mg | Intramuscular |
| Subject | INO-4201 | Vaccine | 1.6 mg | Intramuscular |
| Subject | INO-4201 | Vaccine | 2 mg | Intramuscular |
| Subject | INO-4202 | Vaccine | 2 mg | Intramuscular |
| Subject | INO-4212 | Vaccine | 4 mg | Intramuscular |
| Subject | Rocakinogene Sifuplasmid | Vaccine | 0.2 mg | Intramuscular |
| Subject | Rocakinogene Sifuplasmid | Vaccine | 0.4 mg | Intramuscular |
| Subject | Rocakinogene Sifuplasmid | Vaccine | 1 mg | Intramuscular |